Cargando…

Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR

Sorafenib is the first approved systemic therapy for advanced hepatocellular carcinoma (HCC) and is the first-line choice in clinic. Sustained activation of receptor tyrosine kinases (RTKs) is associated with low efficacy of sorafenib in HCC. Activation of liver X receptor (LXR) has been reported to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Weiqing, Zhu, Wenwei, Lin, Jing, Luo, Mengjun, Lin, Zhifei, Lu, Lu, Jia, Huliang, Qin, Lunxiu, Lu, Ming, Chen, Jinhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911865/ https://www.ncbi.nlm.nih.gov/pubmed/31751859 http://dx.doi.org/10.1016/j.neo.2019.08.002

Ejemplares similares

Prognostic impact of SET domain-containing protein 8 and protein arginine methyltransferase 5 in patients with hepatocellular carcinoma following curative resection
por: Lin, Zhifei, et al.
Publicado: (2018)

(68)Ga-FAPI-04 Versus (18)F-FDG PET/CT in the Detection of Hepatocellular Carcinoma
por: Wang, Hao, et al.
Publicado: (2021)

27‐Hydroxycholesterol promotes metastasis by SULT2A1‐dependent alteration in hepatocellular carcinoma
por: He, Taochen, et al.
Publicado: (2022)

GOLM1 exacerbates CD8(+) T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages
por: Chen, Jinhong, et al.
Publicado: (2021)

In Vivo Screen Identifies Liver X Receptor Alpha Agonism Potentiates Sorafenib Killing of Hepatocellular Carcinoma
por: VÁZQUEZ SALGADO, A. M., et al.
Publicado: (2022)

Organ microenvironment affects growth and metastasis of hepatocellular carcinoma via the TGF-β/Smad pathway in mice
por: LI, GUOCAI, et al.
Publicado: (2013)

Differential combinatorial regulatory network analysis related to venous metastasis of hepatocellular carcinoma
por: Zeng, Lingyao, et al.
Publicado: (2012)

Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Han, Peng, et al.
Publicado: (2017)

The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma
por: Zhang, Yu, et al.
Publicado: (2018)

Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study
por: Ye, Sheng-Long, et al.
Publicado: (2015)

Molecular mechanism of agonism and inverse agonism in ghrelin receptor
por: Qin, Jiao, et al.
Publicado: (2022)

An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET(+) hepatocellular carcinoma
por: Gao, Shan, et al.
Publicado: (2022)

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer
por: Eser, Pınar Özden, et al.
Publicado: (2021)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

Association between Primary Tumor Location and Prognostic Survival in Synchronous Colorectal Liver Metastases after Surgical Treatment: A Retrospective Analysis of SEER Data
por: Wang, Zheng, et al.
Publicado: (2019)

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
por: Jiang, Xiufeng, et al.
Publicado: (2015)

miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR
por: Ji, Lin, et al.
Publicado: (2020)

Involvement of lipid rafts in adhesion-induced activation of Met and EGFR
por: Lu, Ying-Che, et al.
Publicado: (2011)

SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway: SREBP2 Inhibitor sensitizes HCC to lenvatinib
por: Fan, Minghao, et al.
Publicado: (2023)

Structural analysis of the dual agonism at GLP-1R and GCGR
por: Li, Yang, et al.
Publicado: (2023)

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis
por: Hsu, Tung-Wei, et al.
Publicado: (2023)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Biased agonism
por: Kenakin, Terry
Publicado: (2009)

Agonizing Hedgehog
por: Weitzman, Jonathan B
Publicado: (2002)

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

Agon : ballet for twelve dancers
por: Stravinsky, Igor, 1882-1971
Publicado: (1957)

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
por: Lu, Haofeng, et al.
Publicado: (2022)

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
por: Kim, Seongjae, et al.
Publicado: (2023)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways
por: Wang, Hao, et al.
Publicado: (2021)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma
por: Lu, Shuai, et al.
Publicado: (2018)

Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors
por: Sun, Shaofeng, et al.
Publicado: (2017)

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
por: Wu, Fei-Xiang, et al.
Publicado: (2017)

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
por: Shrestha, Ritu, et al.
Publicado: (2021)

Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia
por: Samuelsson, O., et al.
Publicado: (2013)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Cryotherapy is Associated with Improved Clinical Outcomes of Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Yang, Yongping, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_uh3snse3ilb8qkcehaeac6i4dj